103 related articles for article (PubMed ID: 30755497)
21. TAZ upregulates MIR-224 to inhibit oxidative stress response in multiple myeloma.
Abegunde SO; Grieve S; Reiman T
Cancer Rep (Hoboken); 2023 Oct; 6(10):e1879. PubMed ID: 37539777
[TBL] [Abstract][Full Text] [Related]
22. Novel mitochondria-targeting compounds selectively kill human leukemia cells.
Panina SB; Pei J; Baran N; Tjahjono E; Patel S; Alatrash G; Konoplev S; Stolbov LA; Poroikov VV; Konopleva M; Kirienko NV
Leukemia; 2022 Aug; 36(8):2009-2021. PubMed ID: 35672446
[TBL] [Abstract][Full Text] [Related]
23. 3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma.
Feng M; Wang J; Sun M; Li G; Li B; Zhang H
Cancer Cell Int; 2021 May; 21(1):279. PubMed ID: 34039348
[TBL] [Abstract][Full Text] [Related]
24. NRF1-regulated CircNSUN2 promotes lymphoma progression through activating Wnt signaling pathway via stabilizing HMGA1.
Wang L; Yang B; Xu Z; Song X; Gong Z; Xue S; Kong L
Cell Cycle; 2021 May; 20(9):819-828. PubMed ID: 33858292
[TBL] [Abstract][Full Text] [Related]
25. NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy.
Sanghvi VR; Mohan P; Singh K; Cao L; Berishaj M; Wolfe AL; Schatz JH; Lailler N; de Stanchina E; Viale A; Wendel HG
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562682
[TBL] [Abstract][Full Text] [Related]
26. Clinico-pathological and prognostic implications of Srx, Nrf2, and PROX1 expression in gastric cancer and adjacent non-neoplastic mucosa - an immunohistochemical study.
Hafez AM; Harb OA; Alattar AZ; Hefzi N; Ahmed RZ; Shaker SE; Ibrahim A; El-Taher AK
Contemp Oncol (Pozn); 2020; 24(4):229-240. PubMed ID: 33531870
[TBL] [Abstract][Full Text] [Related]
27. The NRF2, Thioredoxin, and Glutathione System in Tumorigenesis and Anticancer Therapies.
Jaganjac M; Milkovic L; Sunjic SB; Zarkovic N
Antioxidants (Basel); 2020 Nov; 9(11):. PubMed ID: 33228209
[TBL] [Abstract][Full Text] [Related]
28. Network-based identification of biomarkers for colon adenocarcinoma.
Hu F; Wang Q; Yang Z; Zhang Z; Liu X
BMC Cancer; 2020 Jul; 20(1):668. PubMed ID: 32680494
[TBL] [Abstract][Full Text] [Related]
29. NRF1 and NRF2 mRNA and Protein Expression Decrease Early during Melanoma Carcinogenesis: An Insight into Survival and MicroRNAs.
Hämäläinen M; Teppo HR; Skarp S; Haapasaari KM; Porvari K; Vuopala K; Kietzmann T; Karihtala P
Oxid Med Cell Longev; 2019; 2019():2647068. PubMed ID: 31687076
[TBL] [Abstract][Full Text] [Related]
30. Prognostic and Predictive Biomarkers in Diffuse Large B-cell Lymphoma.
Chan A; Dogan A
Surg Pathol Clin; 2019 Sep; 12(3):699-707. PubMed ID: 31352982
[No Abstract] [Full Text] [Related]
31. Approaches for vulnerable and frail older patients with diffuse large B-cell lymphomas.
Soubeyran PL; Cordoba R
Curr Opin Oncol; 2019 Sep; 31(5):369-373. PubMed ID: 31335827
[TBL] [Abstract][Full Text] [Related]
32. Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP.
Kari E; Teppo HR; Haapasaari KM; Kuusisto MEL; Lemma A; Karihtala P; Pirinen R; Soini Y; Jantunen E; Turpeenniemi-Hujanen T; Kuittinen O
J Clin Pathol; 2019 Apr; 72(4):316-321. PubMed ID: 30755497
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
Shin HC; Seo J; Kang BW; Moon JH; Chae YS; Lee SJ; Lee YJ; Han S; Seo SK; Kim JG; Sohn SK; Park TI
Korean J Intern Med; 2014 Nov; 29(6):785-92. PubMed ID: 25378977
[TBL] [Abstract][Full Text] [Related]
34. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
[TBL] [Abstract][Full Text] [Related]
35. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
[TBL] [Abstract][Full Text] [Related]
36. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
